CD274 and neoplasm: Immune checkpoint inhibitors (ICIs), which target ICs, such as cytotoxic T-lymphocyte antigen 4 (CTLA-4), programmed death protein 1 (PD-1) or programmed death protein ligand 1 (PD-L1), effectively release the brakes on ICs and restore the anti-tumor immunity (1, 2).